CY1107756T1 - Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων - Google Patents

Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων

Info

Publication number
CY1107756T1
CY1107756T1 CY20071101292T CY071101292T CY1107756T1 CY 1107756 T1 CY1107756 T1 CY 1107756T1 CY 20071101292 T CY20071101292 T CY 20071101292T CY 071101292 T CY071101292 T CY 071101292T CY 1107756 T1 CY1107756 T1 CY 1107756T1
Authority
CY
Cyprus
Prior art keywords
oxidoprogesterone
hydroxy
analogues
novel
sulfate analogs
Prior art date
Application number
CY20071101292T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Pedro Lantos
Adriana Silvia Veleiro
Original Assignee
Laboratoires Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono Sa filed Critical Laboratoires Serono Sa
Publication of CY1107756T1 publication Critical patent/CY1107756T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0078—Sulfur-containing hetero ring containing only sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με καινοτόμα ανάλογα 21-υδροξυ-6,19οξειδοπρογεστερόνης (21OΗ-60Ρ), τη χρήση τους ως αντιγλυκοκορτικοειδή για τη θεραπεία ή/και την πρόληψη νόσων που συνδέονται με πλεόνασμα γλυκοκορτικοειδών. Συγκεκριμένα, η εφεύρεση αφορά τη χρήση των ανωτέρω αναλόγων 21-υδροξυ-6,19-οξειδοπρογεστερόνης (21OΗ-60Ρ) που εμφανίζουν τον τύπο ΤΥΠΟΣ όπου Χ είναι S, SO και S02, και R είναι είτε Η ή OΗ, για τη θεραπεία του συνδρόμου του Cushing, ιατρογενούς υπερκορτιζολισμού ή κατάθλιψης. Επίσης, η παρούσα εφεύρεση σχετίζεται με μεθόδους για την παρασκευή των καινοτόμων αναλόγων 21υδροξυ-6,19-οξειδοπρογεστερόνης (21OΗ-60Ρ).
CY20071101292T 2000-09-18 2007-10-08 Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων CY1107756T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119495 2000-09-18
EP01969729A EP1330468B1 (en) 2000-09-18 2001-09-17 Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids

Publications (1)

Publication Number Publication Date
CY1107756T1 true CY1107756T1 (el) 2013-09-04

Family

ID=8169775

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101292T CY1107756T1 (el) 2000-09-18 2007-10-08 Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων

Country Status (14)

Country Link
US (2) US7053228B2 (el)
EP (1) EP1330468B1 (el)
JP (1) JP2004509132A (el)
AT (1) ATE368683T1 (el)
AU (1) AU8988901A (el)
CA (1) CA2419887C (el)
CY (1) CY1107756T1 (el)
DE (1) DE60129725T2 (el)
DK (1) DK1330468T3 (el)
ES (1) ES2288987T3 (el)
IL (2) IL154775A0 (el)
PT (1) PT1330468E (el)
SI (1) SI1330468T1 (el)
WO (1) WO2002022647A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344273T1 (de) * 2000-09-18 2006-11-15 Applied Research Systems Verfahren zur herstellung von 21-hydroxy-6,19- oxidoprogesteron (21oh-6op)
IL154775A0 (en) * 2000-09-18 2003-10-31 Applied Research Systems 21-hydroxy-6, 19-oxidoprogesterone (21oh-6, 19op) analogues, their preparation and use
CN102190607A (zh) * 2010-03-15 2011-09-21 北京化工大学 一种农药除草剂中间体乙磺酰基乙腈的绿色合成方法
EP2413115A1 (en) * 2010-07-30 2012-02-01 Technische Universiteit Eindhoven Generating a control signal based on acoustic data

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
CZ307995A3 (en) * 1993-05-24 1996-10-16 Immunex Corp Ligands for flt3 receptors
EP1136075B1 (en) 1997-09-21 2003-01-15 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
EP0903146A1 (en) * 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
RS52182B (sr) * 1999-04-23 2012-10-31 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) Farmaceutski preparat
ATE344273T1 (de) 2000-09-18 2006-11-15 Applied Research Systems Verfahren zur herstellung von 21-hydroxy-6,19- oxidoprogesteron (21oh-6op)
IL154775A0 (en) 2000-09-18 2003-10-31 Applied Research Systems 21-hydroxy-6, 19-oxidoprogesterone (21oh-6, 19op) analogues, their preparation and use

Also Published As

Publication number Publication date
IL154775A0 (en) 2003-10-31
DE60129725T2 (de) 2007-12-06
US20050222104A1 (en) 2005-10-06
JP2004509132A (ja) 2004-03-25
US20040029846A1 (en) 2004-02-12
ATE368683T1 (de) 2007-08-15
CA2419887A1 (en) 2002-03-21
CA2419887C (en) 2009-11-10
DE60129725D1 (de) 2007-09-13
EP1330468A1 (en) 2003-07-30
AU8988901A (en) 2002-03-26
IL154775A (en) 2010-12-30
ES2288987T3 (es) 2008-02-01
US7479486B2 (en) 2009-01-20
US7053228B2 (en) 2006-05-30
WO2002022647A1 (en) 2002-03-21
EP1330468B1 (en) 2007-08-01
SI1330468T1 (sl) 2007-10-31
PT1330468E (pt) 2007-09-13
DK1330468T3 (da) 2007-11-05

Similar Documents

Publication Publication Date Title
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
ATE303156T1 (de) Verwendung von gnrh-analogue zur behandlung der harninkontinenz
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
DE50115490D1 (de) Kosmetische zusammensetzung zur behandlung von alternder und/oder gestresster haut
ATE309775T1 (de) Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
BR0113286A (pt) Pirazóis substituìdos
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
GB0223038D0 (en) Therapeutic compounds
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
CY1107756T1 (el) Αναλογα θειου της 21-υδροξυ-6, 19-οξειδοπρογεστερονης (21oh-6οp) για τη θεραπεια πλεονασματος γλυκοκορτικοειδων
ATE421313T1 (de) Verwendung einer dihydrochalcon-reichen phenolischen fraktion für eine kosmetische behandlung
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
SE0004101D0 (sv) New use
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
MY131690A (en) 6-[triazolyl[3-(trifluoromethyl) phenyl]methyl]-2- quinolinones and -quinolinethiones
ATE458495T1 (de) Therapeutische zubereitung für autoimmune erkrankungen